Open Orphan PLC (AIM:ORPH, OTC:OPORF) subsidiary hVIVO's Chief Scientific Officer Andrew Catchpole talks to Proactive London's Katie Pilbeam about the data on their phase 2a study published in the New England Journal of Medicine
hVIVO conducted the Phase 2a, double-blind, placebo-controlled trial using its RSV Human Challenge Study Model.
The trial enrolled 178 healthy adult volunteers across two parts, with people from 18-55 years of age, who were given RSV-A Memphis 37b (“M37b”). Volunteers received either a dose of EDP-938 or placebo for five days after infection, with different dose levels of EDP-938 being assessed.
The study demonstrated that both viral load and clinical symptoms were significantly lower in volunteers that received EDP-938 than those that received placebo, with similar safety profiles between placebo and the antiviral regimens. Importantly, no serious adverse events occurred.